Recent advances in pathologic evaluation and reporting of melanoma

Seminars in Oncology

Volumn 39, Issue 2, 2012, Pages 184-191

  Mathew, Rahel ^a   Messina, Jane L ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER DIAGNOSIS; CANCER GENETICS; CANCER STAGING; DISTANT METASTASIS; HISTOPATHOLOGY; HUMAN; LYMPH NODE; MELANOMA; MOLECULAR DIAGNOSIS; PRIORITY JOURNAL;

CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; LYMPH NODES; MELANOMA; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASM STAGING;

EID: 84859384253     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2012.01.005     Document Type: Article

References (53)

1. C. Erickson, M.S. Driscoll Melanoma epidemic: facts and controversies Clin Dermatol 28 2010 281 286
2. R. Siegel, D. Naishadham, A. Jemal Cancer statistics, 2012 CA Cancer J Clin 62 2012 10 29
3. C.M. Balch, J.E. Gershenwald, S.J. Soong Final version of 2009 AJCC melanoma staging and classification J Clin Oncol 27 2009 6199 6206
4. P.A. Gimotty, D.E. Elder, D.L. Fraker Identification of high-risk patients among those diagnosed with thin cutaneous melanomas J Clin Oncol 25 2007 1129 1134
5. J.F. Thompson, S.-J. Soong, C.M. Balch Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database J Clin Oncol 29 2011 2199 2205
6. D.P. Frishberg, C. Balch, B.L. Balzer Protocol for the examination of specimens from patients with melanoma of the skin Arch Pathol Lab Med 133 2009 1560 1567
7. D.J. Casper, K.I. Ross, J.L. Messina Use of anti-phosphohistone H3 immunohistochemistry to determine mitotic rate in thin melanoma Am J Dermatopathol 32 2010 650 654
8. J.C. Ng, S. Swain, J.P. Dowling, R. Wolfe, P. Simpson, J.W. Kelly The impact of partial biopsy on histopathologic diagnosis of cutaneous melanoma: experience of an Australian tertiary referral service Arch Dermatol 146 2010 234 239
9. C. Kaur, R.J. Thomas, N. Desai The correlation of regression in primary melanoma with sentinel lymph node status J Clin Pathol 61 2008 297 300
10. K.T. Morris, K.J. Busam, S. Bero, A. Patel, M.S. Brady Primary cutaneous melanoma with regression does not require a lower threshold for sentinel lymph node biopsy Ann Surg Oncol 15 2008 316 322
11. J.E. Gershenwald, S.J. Soong, C.M. Balch 2010 TNM staging system for cutaneous melanoma...and beyond Ann Surg Oncol 17 2010 1475 1477
12. V.G. Prieto Sentinel lymph nodes in cutaneous melanoma: handling, examination, and clinical repercussion Arch Pathol Lab Med 134 2010 1764 1769
13. B.M. Clary, M.S. Brady, J.J. Lewis, D.G. Coit Sentinel lymph node biopsy in the management of patients with primary cutaneous melanoma: review of a large single-institutional experience with an emphasis on recurrence Ann Surg 233 2001 250 258
14. J.E. Gershenwald, M.I. Colome, J.E. Lee Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma J Clin Oncol 16 1998 2253 2260
15. A.J. Cochran, D.R. Wen, D.L. Morton Occult tumor cells in the lymph nodes of patients with pathological stage I malignant melanoma An immunohistological study Am J Surg Pathol 12 1988 612 618
16. P.I. Haigh, A. Lucci, R.R. Turner Carbon dye histologically confirms the identity of sentinel lymph nodes in cutaneous melanoma Cancer 92 2001 535 541
17. Scolyer RA, Mihm MC, Cochran AJ, Busam KJ, McCarthy SW. Pathology of melanoma. In: Balch CM, Houghton Jr A, Sober A, Soong SJ (eds). Cutaneous melanoma. Quality Medical Publishing, St. Louis, Missouri, 20548.
18. S.J. Ohsie, G.P. Sarantopoulos, A.J. Cochran, S.W. Binder Immunohistochemical characteristics of melanoma J Cutan Pathol 35 2008 433 444
19. K. Spanknebel, D.G. Coit, S.C. Bieligk, M. Gonen, J. Rosai, D.S. Klimstra Characterization of micrometastatic disease in melanoma sentinel lymph nodes by enhanced pathology: recommendations for standardizing pathologic analysis Am J Surg Pathol 29 2005 305 317
20. A.H. Chakera, B. Hesse, Z. Burak EANM-EORTC general recommendations for sentinel node diagnostics in melanoma Eur J Nucl Med Mol Imaging 36 2009 1713 1742
21. A.J. Cochran, S.J. Ohsie, S.W. Binder Pathobiology of the sentinel node Curr Opin Oncol 20 2008 190 195
22. J.B. Holt, O.P. Sangueza, E.A. Levine Nodal melanocytic nevi in sentinel lymph nodes Correlation with melanoma-associated cutaneous nevi Am J Clin Pathol 121 2004 58 63
23. K.F. Carson, D.R. Wen, P.X. Li, A.M. Lana, C. Bailly, D.L. Morton, A.J. Cochran Nodal nevi and cutaneous melanomas Am J Surg Pathol 20 1996 834 840
24. A.J. Cochran, D.R. Wen, R.R. Huang, H.J. Wang, R. Elashoff, D.L. Morton Prediction of metastatic melanoma in nonsentinel nodes and clinical outcome based on the primary melanoma and the sentinel node Mod Pathol 17 2004 747 755
25. D.J. Dewar, B. Newell, M.A. Green, A.P. Topping, B.W. Powell, M.G. Cook The microanatomic location of metastatic melanoma in sentinel lymph nodes predicts non-sentinel lymph node involvement J Clin Oncol 22 2004 3345 3349
26. J.H. Lee, R. Essner, H. Torisu-Itakura, L. Wanek, H. Wang, D.L. Morton Factors predictive of tumor-positive non-sentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma J Clin Oncol 22 2004 3677 3684
27. M.E. Reeves, R. Delgado, K.J. Busam, M.S. Brady, D.G. Coit Prediction of non-sentinel lymph node status in melanoma Ann Surg Oncol 10 2003 27 31
28. R. Murali, C. Desilva, J.F. Thompson, R.A. Scolyer Non-Sentinel Node Risk Score (N-SNORE): a scoring system for accurately stratifying risk of non-sentinel node positivity in patients with cutaneous melanoma with positive sentinel lymph nodes J Clin Oncol 28 2010 4441 4449
29. A.P.Tvd Ploeg, A.C.J. Akkooi, P. Rutkowski Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria J Clin Oncol 29 2011 2206 2214
30. Y. Kong, S.M. Kumar, X. Xu Molecular pathogenesis of sporadic melanoma and melanoma-initiating cells Arch Pathol Lab Med 134 2010 1740 1749
31. K.T. Flaherty, I. Puzanov, K.B. Kim Inhibition of mutated, activated BRAF in metastatic melanoma N Engl J Med 363 2010 809 819
32. P.M. Pollock, U.L. Harper, K.S. Hansen High frequency of BRAF mutations in nevi Nat Genet 33 2003 19 20
33. K.S. Smalley, V.K. Sondak Melanomaan unlikely poster child for personalized cancer therapy N Engl J Med 363 2010 876 878
34. C.R. Antonescu, K.J. Busam, T.D. Francone L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition Int J Cancer 121 2007 257 264
35. A. Ashida, M. Takata, H. Murata, K. Kido, T. Saida Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas Int J Cancer 124 2009 862 868
36. C. Beadling, E. Jacobson-Dunlop, F.S. Hodi KIT gene mutations and copy number in melanoma subtypes Clin Cancer Res 14 2008 6821 6828
37. J.A. Curtin, K. Busam, D. Pinkel, B.C. Bastian Somatic activation of KIT in distinct subtypes of melanoma J Clin Oncol 24 2006 4340 4346
38. R.S. Rivera, H. Nagatsuka, M. Gunduz C-kit protein expression correlated with activating mutations in KIT gene in oral mucosal melanoma Virchows Arch 452 2008 27 32
39. F.S. Hodi, P. Friedlander, C.L. Corless Major response to imatinib mesylate in KIT-mutated melanoma J Clin Oncol 26 2008 2046 2051
40. Clinical trials http://clinicaltrials.gov/ct2/results?term=melanoma
41. A. Viros, J. Fridlyand, J. Bauer Improving melanoma classification by integrating genetic and morphologic features PLoS Med 5 2008 e120
42. W.H. Koch Technology platforms for pharmacogenomic diagnostic assays Nat Rev Drug Discov 3 2004 749 761
43. K.J. Busam, R. Murali, M. Pulitzer Atypical spitzoid melanocytic tumors with positive sentinel lymph nodes in children and teenagers, and comparison with histologically unambiguous and lethal melanomas Am J Surg Pathol 33 2009 1386 1395
44. R.L. Barnhill, Z.B. Argenyi, L. From Atypical Spitz nevi/tumors: lack of consensus for diagnosis, discrimination from melanoma, and prediction of outcome Hum Pathol 30 1999 513 520
45. W.L. Tom, J.W. Hsu, L.F. Eichenfield, S.F. Friedlander Pediatric "STUMP" lesions: evaluation and management of difficult atypical spitzoid lesions in children J Am Acad Dermatol 64 2011 559 572
46. R.A. Scolyer, R. Murali, S.W. McCarthy, J.F. Thompson Histologically ambiguous ("borderline") primary cutaneous melanocytic tumors: approaches to patient management including the roles of molecular testing and sentinel lymph node biopsy Arch Pathol Lab Med 134 2010 1770 1777
47. L. Ali, T. Helm, R. Cheney, J. Conroy, S. Sait, J. Guitart, P. Gerami Correlating array comparative genomic hybridization findings with histology and outcome in spitzoid melanocytic neoplasms Int J Clin Exp Pathol 3 2010 593 599
48. B.C. Bastian, A.B. Olshen, P.E. LeBoit, D. Pinkel Classifying melanocytic tumors based on DNA copy number changes Am J Pathol 163 2003 1765 1770
49. J. Bauer, B.C. Bastian Distinguishing melanocytic nevi from melanoma by DNA copy number changes: comparative genomic hybridization as a research and diagnostic tool Dermatol Ther 19 2006 40 49
50. P. Gerami, S.S. Jewell, L.E. Morrison Fluorescence in situ hybridization (FISH) as an ancillary diagnostic tool in the diagnosis of melanoma Am J Surg Pathol 33 2009 1146 1156
51. S.R. Dalton, P. Gerami, N.A. Kolaitis Use of fluorescence in situ hybridization (FISH) to distinguish intranodal nevus from metastatic melanoma Am J Surg Pathol 34 2010 231 237
52. P. Gerami, A. Wass, M. Mafee, Y. Fang, M.P. Pulitzer, K.J. Busam Fluorescence in situ hybridization for distinguishing nevoid melanomas from mitotically active nevi Am J Surg Pathol 33 2009 1783 1788
53. P. Pouryazdanparast, M. Newman, M. Mafee, Z. Haghighat, J. Guitart, P. Gerami Distinguishing epithelioid blue nevus from blue nevus-like cutaneous melanoma metastasis using fluorescence in situ hybridization Am J Surg Pathol 33 2009 1396 1400